The PAN-cancer study is a collaboration between the Early Cancer Institute, Owlstone Medical Ltd and Cambridge University Hospitals NHS Foundation Trust. The study is evaluating whether Owlstone Medical’s Breath Biopsy® technology can differentiate between patients with and without different cancer types by comparing breath biomarkers in gastric, oesophageal and liver cancer and healthy volunteers. This study is the first step in evaluating volatile organic compounds analysis as a test to improve early detection rates for cancer with future applicability to primary care.
Further information can be found on the Owlstone Medical PAN Cancer Early Detection website.